Skip to main content
Caplight Logo









UroPharma

UroPharma

Private
NorwichHealthcare & Life Scienceshttps://www.uropharma.com/

Last Round

Early Funding

May 21, 2018

Total Funding Raised

$2.04M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

UroPharma is a MedTech company that develops precision drug-device platforms for direct-to-bladder therapies to treat urological and urogynecological diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

medical devicedrug delivery systemurologydirect-to-bladder therapydtbcathetermedtechprecision medicinebladder healthintravesical therapyurinary tract infectionUTI treatmentoveractive bladderbladder cancerdrug-device combinationurology device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

UroPharma Comparables

Compare UroPharma with similar companies based on industry and business-model similarity.

UroPharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Physion S.r.l.
88%
Combat Medical
82%
Vensica Medical
80%

UroPharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingMay 21, 2018
SeedMay 21, 2018

Key People

Founding team and executive leadership

Howard Shapland

Chief Executive Officer

Executive Team

Scott Glickman

Chief Executive Officer

Executive Team

UroPharma Investors

Notable investors and investment history

UroPharma investors
InvestorRounds
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors increased 59% MoM.

  • Jul 25, 2026

    Monthly visitors grew 187% MoM.

UroPharma Filings

Explore SEC and related filing metadata, where available.

UroPharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about UroPharma's valuation, stock price, and market status.

Is UroPharma a public or private company?

UroPharma is a private company.

What is the current stock price of UroPharma?

UroPharma is a private company, so its shares have no public market price. Caplight tracks UroPharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is UroPharma worth (valuation)?

Valuation information for UroPharma is not publicly available.

Can I buy UroPharma stock?

UroPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was UroPharma's last funding round?

UroPharma's most recent funding round was Early Funding on May 21, 2018.

Who are the main investors in UroPharma?

Key investors in UroPharma include Innovate UK.

Will UroPharma IPO soon?

No public IPO plans have been announced for UroPharma.

How can I track UroPharma secondary market activity?

Caplight tracks bids, offers, and trades in UroPharma's shares on secondary markets.

Firmographic Details

HeadquartersNorwich
Employee Range7
Year Founded2012
Last FundingMay 21, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?